Certified by Founder
Lodge
DISCO Pharmaceuticals GmbH
start up
Germany
- Cologne, North Rhine-Westphalia
- 17/01/2024
- Seed
- $21,727,000
DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.
- Industry Pharmaceutical Manufacturing
- Website https://discopharma.de/
- LinkedIn https://www.linkedin.com/company/disco-pharmaceuticals-gmbh/about/
Kilo Code | $8,000,000 | (Dec 11, 2025)
Surf AI | $15,000,000 | (Dec 11, 2025)
Bobyard | $35,000,000 | (Dec 11, 2025)
Empromptu.ai | $2,000,000 | (Dec 11, 2025)
Radial | $50,000,000 | (Dec 11, 2025)
Channel3( YC S25) | $6,000,000 | (Dec 11, 2025)
D3 Bio | $108,000,000 | (Dec 11, 2025)
Sprouty | $550,000 | (Dec 11, 2025)
Fresco | $17,550,941 | (Dec 11, 2025)
BoodleBox | $5,000,000 | (Dec 11, 2025)
CoreOps.AI | $3,500,000 | (Dec 10, 2025)
BON Credit | $3,500,000 | (Dec 10, 2025)